Â
RAD 001 - Everolimus (AFINITOR ®) in advanced neuroendocrine tumors
Patients with advanced neuroendocrine tumor, in which standard therapy has become ineffective, can access the compassionate use program of Everolimus. Not yet available with this indication, Everolimus has shown significant antitumor efficacy in preclinical studies.
Â
No current events.
web project & administrator - data coordinator:
Dario Piazza - U.O. Oncologia Medica (chair: Prof. N. Gebbia) - A.O.U.P. "P. Giaccone" Palermo, Italy
© 2010 - all right reserved
